Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
Eur Respir J
.
2024 Apr 4;63(4):2400395.
doi: 10.1183/13993003.00395-2024.
Print 2024 Apr.
Authors
Alberto Papi
1
2
,
Diogenes S Ferreira
3
2
,
Thomy Tonia
4
,
Florence Schleich
5
6
2
Affiliations
1
Respiratory Medicine, University of Ferrara, Ferrara, Italy ppa@unife.it.
2
Task force co-chairs.
3
Private Practice, Allergy and Immunology, Belo Horizonte, Brazil.
4
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
5
Respiratory Medicine, CHU of Liege, Liege, Belgium.
6
GIGA I3 University of Liege, Liege, Belgium.
PMID:
38575164
DOI:
10.1183/13993003.00395-2024
No abstract available
Publication types
Letter
Comment
MeSH terms
Asthma* / drug therapy
Budesonide
Formoterol Fumarate / therapeutic use
Humans
Substances
Formoterol Fumarate
Budesonide